Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02663518 · OUTCOME

Part 2: Overall Response Rate (ORR)- Bohnsack 2014- Disease Indication

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors · Source last updated 2024-05-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)

What was measured

ORR is presented in this outcome measure as number of responders. Responders were those who had irComplete Response, IrPartial Response. Immune-Related Response Criteria: RECIST (Bohnsack et al., 2014) was used for assessment of tumor. Tumor types evaluated included Small Cell Lung Cancer (SCLC).

Analysis population: Full analysis set included all participants who received at least 1 dose of study treatment. "Number of Participants Analyzed" refers to participants evaluable for this outcome measure.

Groups in this outcome

Part 2: Small Cell Lung Cancer (SCLC)

Participants with SCLC who received study drug in part 2.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 2: Small Cell Lung Cancer (SCLC)4

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 2: Small Cell Lung Cancer (SCLC)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    units
    Participants
description
ORR is presented in this outcome measure as number of responders. Responders were those who had irComplete Response, IrPartial Response. Immune-Related Response Criteria: RECIST (Bohnsack et al., 2014) was used for assessment of tumor. Tumor types evaluated included Small Cell Lung Cancer (SCLC).
groups
  1. description
    Participants with SCLC who received study drug in part 2.
    id
    OG000
    title
    Part 2: Small Cell Lung Cancer (SCLC)
param Type
COUNT_OF_PARTICIPANTS
population Description
Full analysis set included all participants who received at least 1 dose of study treatment. "Number of Participants Analyzed" refers to participants evaluable for this outcome measure.
reporting Status
POSTED
time Frame
From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)
title
Part 2: Overall Response Rate (ORR)- Bohnsack 2014- Disease Indication
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice